Conventional dose of estrogen

PreclinicalSmall molecule

TThe Third Xiangya Hospital of Central South University

Conventional dose of estrogen is one of 33 small molecule programs targeting Abortion. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbortionActive, not recruiting

AbortionPreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Abortion

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Approved

34 2

Mifeprex

DDanco

Approved

22 3

Dostinex

Pfizer

Approved

3 4

Amidate

Pfizer

Approved

1 5

Xylocaine

MMEDRx USA, Inc.

Approved

5 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 7

Duragesic

CCephalon

Approved

2 8

Prometrium

Ferring

Approved

2 9

Pitocin

RRetrophin

Approved

1 10

Versed

CConrado Roberto Hoffmann Filho

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2035

N/ARecruiting

Abortion

NCT07422506

Clinical

Trials by Indication[1]

Abortion1 trial

A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion

Recruiting·TThe Third Xiangya Hospital of Central South University·N/A·NCT07422506·580 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Conventional dose of estrogen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Conventional dose of estrogen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Conventional dose of estrogen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Third Xiangya Hospital of Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Third Xiangya Hospital of Central South University

Conventional dose of estrogen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2035

Trials by Indication[1]

Abortion1 trial

References

Drug Info

Quick Facts

Related News